Short- and long, duration responses to levodopa during the first year of levodopa therapy

Annals of Neurology

Volumn 42, Issue 3, 1997, Pages 349-355

  Nutt, John G ^a   Carter, Julie H ^a   Van Houten, Laura ^a   Woodward, William R ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; BRADYKINESIA; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; MALE; MOTOR PERFORMANCE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIPARKINSON AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; TIME FACTORS;

EID: 0030799456     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420311     Document Type: Article

References (22)

1. Marsden CD. "On-off" phenomena in Parkinson's disease. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's disease: current progress, problems and management. Amsterdam: Elsevier/ North-Holland Biomedical Press, 1980:241-254
2. Chase TN, Baronti F, Fabbrini G, et al. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989;39(suppl 2):7-10
3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276:374-379
4. Muenter MD, Tyce GM. L-DOPA therapy of Parkinson's disease: plasma L-DOPA concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239
5. Nutt JG, Carter JH, Woodward WR. Long duration response to levodopa. Neurology 1995;45:1613-1616
6. Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488
7. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson's disease. London: Macmillan, 1987:153-163
8. Quattrone A, Zappia M, Aguglia U, et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995;38:389-395
9. Olanow CW, Hauser RA, Gauger LL, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777
10. Gancher ST, Nutt JG, Woodward WR. Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations. Neurology 1988;38:712-716
11. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neurol 1992;49:1123-1130
12. Hughes AJ, Frankel JP, Kempster PA, et al. Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. J Neurol Neurosurg Psychiatry 1994;57:430-434
13. Colosimo C, Merello M, Hughes AJ, et al. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996;61: 634-637
14. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24:366-371
15. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573
16. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44
17. Stolz G, Aschoff JC, Born J, Aschoff J. VEP, physiological and psychological circadian variations in humans. J Neurol 1988; 235:308-313
18. Comella CL, Bohmer J, Stebbins GT. Sleep benefit in Parkinson's disease. Neurology 1995;45(Suppl 4):A286 (Abstract)
19. Rusk GD, Siemers ER. Diurnal variation in motor ability in Parkinson's disease. Ann Neurol 1993;34:266-267 (Abstract)
20. Fink JK, Barton N, Cohen W, et al. Dystonia with marked diurnal variation associated with biopterin deficiency. Neurology 1988;38:707-711
21. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1992; 41:174-181
22. Harwood G, Hierons R, Fletcher NA, Marsden CD. Lessons from a remarkable family with dopa-responsive dystonia. J Neurol Neurosurg Psychiatry 1994;57:460-463